Nnc1679-0001

Phase 1

Novo Nordisk

Nnc1679-0001 is one of 14 therapeutic programs targeting Diabetes Mellitus, Type 2. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Diabetes Mellitus, Type 2Recruiting

Diabetes Mellitus, Type 2Phase 1

Recruiting

Competition

Competitive Landscape

21 competitors in Diabetes Mellitus, Type 2

#DrugCompanyPhaseTrials

Ozempic

Novo Nordisk

Approved

4 2

Glucophage

EMD Serono

Approved

1 3

Foundayo

Eli Lilly

Phase 3

2 4

Trulicity

Eli Lilly

Phase 3

1 5

High-Dose

XXiangbei Welman Pharmaceutical Co., Ltd

Approved

1 6

Low Dose

Boehringer Ingelheim

Approved

1 7

Jardiance

Boehringer Ingelheim

Phase 3

2 8

Vicadrostat

Boehringer Ingelheim

Phase 3

1 9

Cagrisema

Novo Nordisk

Phase 2

1 10

LY3938577

Eli Lilly

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 1Recruiting

Diabetes Mellitus, Type 2

NCT07570992

Clinical

Trials by Indication[1]

Diabetes Mellitus, Type 21 trial

A Phase 1,Double-blinded,Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of NNC1679-0001 When Administered to Healthy Participants and Participants With T2DM

Recruiting· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT07570992·58 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Nnc1679-0001. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Nnc1679-0001. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Novo Nordisk company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: Novo Nordisk

Nnc1679-0001

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Diabetes Mellitus, Type 21 trial

References

Drug Info

Quick Facts

Related News